ARCHIVES

ODAC Recommends Femara Campath For FDA Approval.

This article is from The Cancer Letter archive.

Vol. 27 No. 01 | January 5, 2001

Download PDF Visit The Full Archive

Related Articles

About Face; NCI To Keep Preclinical AIDS Drug Development

December 12, 1986

NCI Shakeup Possibilities Grow; Marc Lippman To Head Lombardi Center; DCT Could Lose CTEP

March 11, 1988

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

November 29, 2013

New Colorado Center Gets Core Grant

February 5, 1988

Gallo’s Lab Moved From DCT to DCE; NCI Planning To Drop “Cancer Treatment Reports” At End Of ‘86

February 6, 1987

Dingell Subcommittee Report Next Month To Include New Info

July 1, 1994